Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation.

Article Details

Citation

Copy to clipboard

Light JA, Sasaki TM, Ghasemian R, Barhyte DY, Fowlkes DL

Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation.

Clin Transplant. 2002;16 Suppl 7:30-3.

PubMed ID

12372041 [ View in PubMed

]

Abstract

Tacrolimus inhibits lymphocyte responses by blocking calcium-dependent signalling pathways important in IL-2 generation. Daclizumab, a humanized monoclonal antibody, binds with high affinity to the Tac subunit of the IL-2 receptor complex. We reasoned therefore that the absence of IL-2R should permit lower doses of tacrolimus and thereby less toxicity. Twenty-eight patients were randomized and followed for 6 months: Group 1, high dose (HD) tacrolimus (trough 12-17 ng/mL; n = 13); Group 2, low dose (LD) tacrolimus (trough 5-10 ng/mL; n = 15). All patients received daclizumab induction (2 mg/kg) on days 0 and 14, mycophenolate mofetil (2 g/d except for one patient who received 1 g) and rapid prednisone taper. Serious infections were minimal in both groups. Hospitalizations, for various reasons, were HD (n = 12) and LD (n = 6). All patients and grafts survived for the 6-month study period. There was one rejection episode in a non-compliant patient at 101 d. LD tacrolimus appears equally effective as HD tacrolimus in preventing rejection episodes and may be associated with fewer adverse events.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Daclizumab	Interleukin-2 receptor subunit beta	Protein	Humans	Yes	Antibody	Details